Compare WHF & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHF | ADCT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 136.1M |
| IPO Year | 2012 | 2019 |
| Metric | WHF | ADCT |
|---|---|---|
| Price | $6.93 | $1.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $7.83 | $3.33 |
| AVG Volume (30 Days) | 98.1K | ★ 1.2M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 14.93% | N/A |
| EPS Growth | ★ 31.91 | 30.86 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | $26.43 |
| P/E Ratio | $15.93 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $6.07 | $0.78 |
| 52 Week High | $7.84 | $4.98 |
| Indicator | WHF | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 63.34 |
| Support Level | $6.87 | $0.99 |
| Resistance Level | $7.22 | $1.45 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 18.31 | 95.33 |
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).